212 related articles for article (PubMed ID: 11205899)
1. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.
Suzuki K; Fueyo J; Krasnykh V; Reynolds PN; Curiel DT; Alemany R
Clin Cancer Res; 2001 Jan; 7(1):120-6. PubMed ID: 11205899
[TBL] [Abstract][Full Text] [Related]
2. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
3. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
[TBL] [Abstract][Full Text] [Related]
4. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses.
Suzuki K; Alemany R; Yamamoto M; Curiel DT
Clin Cancer Res; 2002 Nov; 8(11):3348-59. PubMed ID: 12429621
[TBL] [Abstract][Full Text] [Related]
5. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors.
van Beusechem VW; Mastenbroek DC; van den Doel PB; Lamfers ML; Grill J; Würdinger T; Haisma HJ; Pinedo HM; Gerritsen WR
Gene Ther; 2003 Nov; 10(23):1982-91. PubMed ID: 14528322
[TBL] [Abstract][Full Text] [Related]
6. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
[TBL] [Abstract][Full Text] [Related]
7. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
[TBL] [Abstract][Full Text] [Related]
8. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
9. Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells.
Iguchi K; Sakurai F; Tomita K; Katayama K; Yamaguchi T; Kawabata K; Tagawa M; Kawabata M; Shirakawa T; Mizuguchi H
Cancer Gene Ther; 2012 Feb; 19(2):118-25. PubMed ID: 22076042
[TBL] [Abstract][Full Text] [Related]
10. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.
Rajecki M; Kanerva A; Stenman UH; Tenhunen M; Kangasniemi L; Särkioja M; Ala-Opas MY; Alfthan H; Sankila A; Rintala E; Desmond RA; Hakkarainen T; Hemminki A
Mol Cancer Ther; 2007 Feb; 6(2):742-51. PubMed ID: 17308070
[TBL] [Abstract][Full Text] [Related]
11. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
[TBL] [Abstract][Full Text] [Related]
12. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
[TBL] [Abstract][Full Text] [Related]
13. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo.
Witlox AM; Van Beusechem VW; Molenaar B; Bras H; Schaap GR; Alemany R; Curiel DT; Pinedo HM; Wuisman PI; Gerritsen WR
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):61-7. PubMed ID: 14734452
[TBL] [Abstract][Full Text] [Related]
14. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
[TBL] [Abstract][Full Text] [Related]
15. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
16. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
17. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.
Zhu ZB; Makhija SK; Lu B; Wang M; Rivera AA; Kim-Park S; Ulasov IV; Zhou F; Alvarez RD; Siegal GP; Curiel DT
Int J Oncol; 2005 Jul; 27(1):237-46. PubMed ID: 15942665
[TBL] [Abstract][Full Text] [Related]
18. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer.
Yamamoto M; Davydova J; Wang M; Siegal GP; Krasnykh V; Vickers SM; Curiel DT
Gastroenterology; 2003 Oct; 125(4):1203-18. PubMed ID: 14517802
[TBL] [Abstract][Full Text] [Related]
19. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus.
Lee CT; Park KH; Yanagisawa K; Adachi Y; Ohm JE; Nadaf S; Dikov MM; Curiel DT; Carbone DP
Cancer Res; 2004 Sep; 64(18):6660-5. PubMed ID: 15374981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
